Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-ASH 2024 CML Highlights
24 January 2025 | Virtual Meeting
Post-ASH 2024 CML Highlights
Featuring presentations & discussions on selected CML abstracts from the 66th ASH Annual Meeting and Exposition
Friday 24 January | 10:00 – 12:00 CST/ 16:00 – 18:00 GMT/ 17:00 – 19:00 CET
Chair: Jorge Cortes | Moderators: Elisabetta Abruzzese & Mhairi Copland
The Post-ASH 2024 CML Highlights was supported by Incyte. Supporters have no influence over the production of content.
Explore all presentations and panel discussions below:
Session 1: Latest evidence with asciminib
Updates from the Phase III ASC4FIRST study
Jorge Cortes Georgia Cancer Center, Augusta University, Augusta, GA, United States
Activity of asciminib in patients with T315I-mutated CML-CP
Jorge Cortes Georgia Cancer Center, Augusta University, Augusta, GA, United States
Retrospective study comparing asciminib vs ponatinib in 99 patients with T315I-mutated CML
Maria Agustina Perusini Princess Margaret Cancer Centre, Toronto, Canada
Update of the Ascend-CML study of frontline asciminib
David Yeung University of Adelaide, Adelaide, Australia
Panel discussion
Session 2: Advances with additional therapies in CML
A CML Campus study: transitioning from high-potency to low-potency inhibitors in CML
Elisabetta Abruzzese S. Eugenio University Hospital, Rome, Italy
Five-year follow-up of the Phase II OPTIC study in patients with CP-CML
Jorge Cortes Georgia Cancer Center, Augusta University, Augusta, GA, United States
Panel discussion
Session 3: Impact of mutations and cytokine levels on treatment outcomes in CML
Association between cancer gene variants at diagnosis & emergence of resistance in CML patients despite frontline treatment with BCR::ABL1 inhibitors
Naranie Shanmuganathan Royal Adelaide Hospital and SA Pathology, Adelaide, Australia
ASXL1 mutations at diagnosis did not impact depth of MR & TFR eligibility in patients with CP-CML receiving nilotinib or imatinib in the SUSTRENIM trial
Simona Soverini University of Bologna, Bologna, Italy
Early and sensitive detection of blood cancer-related gene variants in patients with CML predicts treatment failure
Susan Branford University of Adelaide, Adelaide, Australia
Molecular outcome of patients with CML not in deep molecular response: the "others" from the Gimema Labnet Network
Fabrizio Pane Federico II University, Naples, Italy
Panel discussion
